title: Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
abstract: BACKGROUND
  Methotrexate (MTX) is a folate analogue used in the treatment of moderate to severe psoriasis and rheumatoid arthritis (RA). It oppositely affects inflammation and hyperhomocysteinemia-two independent risk factors for vascular disease. To date, there are no published reports evaluating the impact of these potentially paradoxical action of MTX.
  
  
  OBJECTIVE
  The purpose of this study was to evaluate the effect of MTX therapy on the incidence of vascular disease in patients with psoriasis and RA.
  
  
  METHODS
  We conducted a retrospective cohort study in which we analyzed computerized records of 7,615 outpatients diagnosed with psoriasis and 6,707 with RA at the Veterans Integrated Service Network 8.
  
  
  RESULTS
  Patients prescribed MTX therapy had a significantly reduced risk of vascular disease compared to those who were not prescribed MTX (psoriasis: RR = 0.73, 95% CI = 0.55-0.98; RA: 0.83, 0.71-0.96). This reduction was most evident for patients prescribed a low cumulative dose of MTX (psoriasis: RR = 0.50, 95% CI = 0.31-0.79; RA = 0.65, 0.52-0.80). Concomitant use of folic acid (FA) with MTX also reduced the incidence of vascular disease in patients prescribed MTX (psoriasis: RR = 0.56, 95% CI = 0.39-0.80; RA: 0.77, 0.38-1.56).
  
  
  CONCLUSIONS
  MTX therapy reduced the incidence of vascular disease in veterans with psoriasis or RA. Low to moderate cumulative dose appears more beneficial than the higher dose. We hypothesize that this effect is caused by its anti-inflammatory properties. In addition, a combination of MTX and FA led to a further reduction in the incidence of vascular disease.
authors.affiliation: Department of Dermatology, Veterans Administration Medical Center, Miami, Florida 33125, USA.
authors.forename: Srdjan
authors.initials: S
authors.lastname: Prodanovich
authors.forename: Srdjan
authors.initials: S
authors.lastname: Prodanowich
authors.forename: Fangchao
authors.initials: F
authors.lastname: Ma
authors.forename: J Richard
authors.initials: JR
authors.lastname: Taylor
authors.forename: Candido
authors.initials: C
authors.lastname: Pezon
authors.forename: Tahira
authors.initials: T
authors.lastname: Fasihi
authors.forename: Robert S
authors.initials: RS
authors.lastname: Kirsner
mesh_terms: D000368:Aged; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D015331:Cohort Studies; D015897:Comorbidity; D016208:Databases, Factual; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005431:Florida / Q000453:epidemiology; D005492:Folic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D020138:Hyperhomocysteinemia / Q000139:chemically induced / Q000517:prevention & control; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D008297:Male; D016347:Medical Records Systems, Computerized; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D012306:Risk; D014652:Vascular Diseases / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D014728:Veterans
chemical_list: D007166:Immunosuppressive Agents; D005492:Folic Acid; D008727:Methotrexate